{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000045","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.213256+00:00","generated_at":"2026-05-31T07:12:00.166560+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté","bullets":["94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.","75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.","No drug-related serious adverse events; adverse events were mild-to-moderate and transient.","Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.","Improvements also seen in crepiness, hydration, and radiance in both cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000045","json":"https://secwatch.observer/filing/0001711279-24-000045.json","markdown":"https://secwatch.observer/filing/0001711279-24-000045.md","text":"https://secwatch.observer/filing/0001711279-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/0001711279-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/krys-20240828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:12:00.166560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}